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Abstract 
Purpose: The current tumor–node–metastasis (TNM) classification system has been used for many years. 
The prognosis of patients with metastatic prostate cancer (mPC) treated using primary androgen 
deprivation therapy (PADT) was analyzed according to the TNM classification. 
Methods: A total of 5,618 cases with lymph node metastases only (N1M0), non-regional lymph node 
metastasis (M1a), bone metastasis (M1b), and distant metastasis (M1c) were selected from the Japanese 
Study Group of Prostate Cancer database. Overall survival (OS), cancer-specific survival (CSS), and 
progression-free survival (PFS) rates were calculated using Kaplan–Meier analysis. The influence of 
clinical variables on patient prognosis was evaluated using the Cox’s proportional hazard regression 
model. 
Results: The 5-year OS, CSS, and PFS were 76.0, 83.2, and 38.8 % in N1M0, 57.5, 69.0, and 23.0 % in 
M1a, 54.0, 63.1, and 23.0% in M1b, and 40.0, 51.5, and 16.6% in M1c, respectively. OS, CSS, and PFS 
worsened as the stages progressed. OS, CSS and PFS were all significantly worse in N1M1b compared 
with N0M1b. Multivariate analysis revealed that OS and CSS were worse in patients with a Gleason score 
≥ 8, and that combined androgen blockade (CAB) treatment provided better OS than non-CAB treatments 
at any tumor stage. However, OS and CSS were worse in individuals with a prostate-specific antigen > 
100 ng/ml only in M1b. 
Conclusions: Patient prognosis worsened with stage progression, therefore, current TNM classification 
system of mPC for PADT was shown to be trustworthy. Each PC cell that develops bone or lymphoid 
metastasis may exhibit different characteristics.  
 
Introduction 
Prostate cancer is one of the most common cancers in males worldwide [1]. Some reports have suggested 
that prostate-specific antigen (PSA) screening contributes to the detection of early stage prostate cancer, 
and hence, the mortality rate from prostate cancer has been decreasing [2]. However, 10-20% of prostate 
cancer patients are diagnosed with metastatic disease, even today [3]. Androgen deprivation therapy 
(ADT) is usually selected as the first line therapy for metastatic prostate cancer (mPC). Nevertheless, the 
effectiveness of ADT is generally not permanent, and treatment selection for castration-resistant prostate 
cancer (CRPC) can be challenging [4]. The effectiveness of docetaxel [5] and other new drugs [6-8] for 
CRPC has been reported; however, the improvement in the prognosis of those patients is still not 
sufficient. The effectivenesses of primary ADT (PADT) are thought to have huge impacts on the 
prognosis of patients with mPC. 
The tumor–node–metastasis (TNM) classification system was published by the Union for International 
Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC), and is used for the staging 
of malignant tumors, including prostate cancer. The staging determined by the TNM classification system 
is thought to correlate closely with cancer prognosis; therefore, the staging affects the treatment plan. The 
TNM classification system has been revised several times, and the current edition was the seventh. The 
TNM classification of mPC has not changed since the fourth edition published in 1992. Regional lymph 
node metastasis is classified to N1, distant lymph node metastasis is classified as M1a, bone metastasis is 
classified as M1b, and other sites of distant metastasis are classified as M1c [9]. The most common 
metastatic sites of PC are the bones, and the frequency of metastases to other sites, including the lymph 
nodes or viscera, is lower [10, 11]. A recent report showed that the prognosis of metastatic CRPC with 
visceral metastasis was unfavorable [12]. Although the current TNM classification system has been used 
for many years, no sufficient evaluation of patient prognosis according to the mPC subcategory classified 
by the TNM system has been performed to date. In Japan, the Japanese Study Group of Prostate Cancer 
(J-CaP) study, which was performed to evaluate the therapeutic value of PADT for PC, registered 26,000 
cases from 2001 to 2003, and the cases were followed up to the present day. In the current study, mPC 
cases that had been followed up prospectively for over 10 years were extracted from this cohort and 
analyzed to evaluate the therapeutic value of PADT according to tumor stage determined using the TMN 
classification system.  
 
Materials and methods 
Patients and background 
A total of 26,272 patients who started ADT between 2001 and 2003 were registered at 385 institutions 
throughout Japan in the J-CaP study [13]. The data collection procedures were approved by the local and 
central institutional review boards. Of these cases, 5,618 N1M0, M1a, M1b, and M1c cases were included 
in the current study; however, 359 cases of M1x (an unclear M1 subcategory) were excluded. Generally, 
the registered cases were updated every 3 months with progression data including survival and disease 
progression. The patients were followed until September 30, 2014. The patients were diagnosed by 
prostate biopsy at each institution, and the N and M staging was determined by the results of imaging 
findings such as bone scintigraphy, magnetic resonance imaging, and computed tomography. The clinical 
stage was determined based on the fifth edition of the TNM classification published in 1997 [14]. 
PADT was performed using flutamide, chrolmadinone acetate (CMA), or diethyl stilbestrol (DES) as 
anti-androgens (AAs), and 1-month or 3-month preparations of goserelin or lauprolide as luteinizing 
hormone-releasing hormone (LHRH) agonists. LHRH or castration + AA was performed in 3,864 patients 
(69%), compared with LHRH monotherapy in 519 patients (9%), castration monotherapy in 288 patients 
(5%), LHRH or castration + short AA in 338 patients (6%), and other treatments in 609 patients (11%). 
Short AA was defined as AA therapy given between 30 days before and 60 days after the start of LHRH 
for flare prevention [15]. LHRH analog or castration + AA were classified as CAB, whereas LHRH or 
castration monotherapy, LHRH or castration monotherapy + short AA and other treatments were 
classified as non-CAB. 
 
Statistical analysis 
Patients were followed until death or until they withdrew from the study. Events for PFS were determined 
by clinicians according to rising PSA levels. PSA failure was determined as a PSA level at least 2.0 ng/ml 
higher and a 25% rise from the nadir level, which was confirmed by a second PSA test at least 4 weeks 
later. The relationships among demographic data were assessed using chi-squared tests. One-way analysis 
of variance was performed for comparisons of three or more groups with Tukey’s HSD post-hoc test. 
Pearson’s correlation coefficient was used to determine the relationships among age, PSA, and GS. OS, 
CSS, and PFS were calculated using the Kaplan–Meier method. Events taken into account to calculate OS 
and CSS were death for any reason and cancer-related deaths, respectively. The events taken into account 
for the calculation of PFS were PSA failure, clinical failure, and death. Differences among groups were 
assessed using log-rank tests. The influences of the clinical variables that affected prognosis were 
evaluated using Cox’s proportional hazard regression model. All data analyses were performed using 




The demographic data available from the database are shown in Table 1. Regarding age, patients with 
M1b tumors were significantly older than were those in the other groups. PSA levels tended to increase as 
the stage progressed. The GS was significantly higher in the M1a group compared with the other groups. 
There was no significant difference in the proportion of patients that received CAB among groups. After a 
mean follow-up of 3.3 years 1,923 patients (34.2%) died, of which 1,364 (24.3%) were PC-specific 
deaths. Figure 1 shows the OS, CSS, and PFS in all groups, as well as the hazard ratios (HRs) analyzed 
using the Cox hazard model. OS, CSS, and PFS declined as the stage progressed; however, there were no 
statistically significant differences between M1a and M1b cases. The 5-year OS was 76.0 % in the N1M0, 
57.5 % in M1a, 54.0 % in M1b, and 40.0 % in M1c cases (Figure 1A). There was no significant 
difference in CSS between the M1a and M1b groups. The 5-year CSS was 83.2 % in the N1M0, 69.0 % in 
M1a, 63.1 % in M1b, and 51.5 % in M1c cases (Figure1 B). There was no significant different in the PFS 
of patients that received PADT between the M1a and M1b groups. The 5-year PFS was 38.8 % in the 
N1M0, 23.0 % in M1a, 23.0 % in M1b, and 16.6 % in M1c cases (Figure 1C). 
Among the patients in the M1b group, the 2,445 cases of N0M1b and the 1,607 cases of N1M1b were 
compared. The mean age, PSA, and GS were 74.2 years, 651 ng/ml, and 7.6 in the N0M1b group, 
compared with 72.5 years old, 1,325 ng/ml, and 8.0 in N0M1b, respectively; the differences between any 
of these were considered significantl at p < 0.001. The 5-year OS was 58.9% [95% confidence interval 
(CI) 56.3-61.5] in the N0M1b, compared with 46.2 % (95%CI 43.0-49.4) in N1M1b. The 5-year CSS was 
69.4 % (95%CI 66.8-72.0) in the N0M1b, compared with 54.8 % (95%CI 51.5-58.1) in the N1M1b. 
Finally, the 5-year PFS was 28.3 % (95%CI 26.1-30.5) in the N0M1b, and 15.5 % (95%CI 13.3-17.7) in 
the N1M1b; the differences between any of these were considered significant at p < 0.001.  
The effects of age, GS, PSA, and the type of ADT on OS and CSS were analyzed using multivariate 
analysis. The OS of patients aged > 75 years was shorter than was that of patients aged ≤ 75; however, 
there was no such differences were observed in M1a cases.  The OS of patients with a GS ≥ 8 was worse 
than was that of individuals with a GS of ≤ 7. The OS of patients with a PSA > 100 ng/ml was 
significantly worse in only patients with M1b disease; however, the OS of patients with a PSA of ≤ 100 
ng/ml was significantly worse in individuals with M1a disease. Conversely, PSA had no effect on the 
prognosis of patients with N1M0 and M1c disease. The OS of patients treated using CAB was higher than 
was that of those treated using non-CAB at all stages (Table 2). The CSS of all groups with a GS ≥ 8 was 
significantly shorter compared with a GS ≤ 7, and CSS were not affected by age in any groups. The CSS 
of after CAB treatment was significantly higher than that after non-CAB treatments in all groups except 
M1a. The CSS of patients with M1b disease and a PSA ≥ 100 ng/ml was significantly shorter than those 
with a PSA < 100 ng/ml; however, there was no significant difference in CSS among the N1M0 and M1c 
groups. In contrast, CSS in patients with M1a disease was worse in those with a PSA ≥ 100 ng/ml than in 
those with a PSA < 100 ng/ml (Table 3). There were no significant correlations among age, PSA, and GS 
in the N1M0, M1a, and M1c groups. However, there were significant correlations between age and GS (R 
= −0.58, p < 0.001) and PSA and GS (R = 0.55, p = 0.001) in the M1b group. 
 
Discussion 
The current M stage of PC has been determined using the fourth edition of the TNM classification system 
since 1992 [9]. The effects of treating mPC using PADT, according to subgroups separated by M stage, 
have not been evaluated in detail. In the current study, the prognosis and factors that influence PADT for 
mPC in subgroups defined by the current TNM classification were analyzed. The most common 
metastatic site of PC was the bone in 84 % of the aggregate results from 74,826 PC cases in the United 
States [10]. In the current study, M1b was the metastatic category of 78% of cases in the TNM 
classification, which was likely the result of a high frequency of bone metastasis, consistent with previous 
reports. The mean patient age was higher in the M1b group compared with the other subcategories, with 
the peak age of 70–74 years. The PSA level at diagnosis increased with stage progression. The mean GS 
was significantly higher in the M1a group than in other groups. OS and CSS deteriorated as the tumor 
stage progressed; however, there was no significant difference between M1a and M1b. The trends in PFS 
were the same as those in OS and CSS. As such, the efficacy of PADT was considered to affect the 
prognosis of the patients. Patients with M1c disease, including visceral metastasis, had the worst 
prognosis. Previous reports showed that PC patients with extensive metastasis had poor prognosis [16], 
and that the poor prognosis of CRPC was also reported to be highly affected by liver and lung metastasis, 
in that order of decreasing influence, regardless of other metastases including bone [12]. In the current 
study, multivariate analysis revealed that OS was significantly higher in patients treated using CAB 
compared with than non-CAB, with HRs 0.63–0.75 in all subcategories except M1a. 
Patients aged > 75 years had poor OS in all stages; however, there was no significant difference in CSS 
among any age groups. Patients with a GS ≥ 8 had significantly worse OS and CSS in all stages. OS and 
CSS were also significantly worse in patients with M1b disease and a PSA ≥ 100 ng/ml. CSS was also 
worse in M1a patients with a PSA < 100 ng/ml. However, PSA level had no significant effect on patients 
with other stage disease. A significant correlation between PSA level and the frequency of bone 
metastasis was reported previously [17, 18]. In addition, there was no significant correlation between PSA 
level and the metastatic pattern, except for bone metastasis, in a previous report [11]. Patients with M1a 
disease subtype and systemic lymph node metastasis had different characteristics from those with M1b 
disease and bone metastasis, such as higher GS, the absence of correlation between PSA and disease 
prognosis such as OS or CSS, and a low effect of CAB as the PADT. M1a is categorized as systemic 
lymph node metastasis, and we did not analyze how many cases with M1b disease had systemic lymph 
node metastasis in the current study. When patients with N0M1b and N1M1b disease were compared, OS, 
CSS, and PFS were significantly worse in the N1M1b group compared with N0M1b, regardless of the 
higher age in the N1M1b group. 
PC is a complex multifaceted and biologically heterogeneous disease [19]; therefore, each PC cell may 
have different characteristics, react differently to treatment, and have favorable sites and patterns that 
support its metastatic proliferation, such as hematogenous or lymphogenous metastasis. The prognosis of 
patients in the current study became poor as the tumor stage progressed from N1M0 to M1c; however, 
both the chronological extension and metastatic pattern should be considered to better understand the 
mPC status of individual patients. The current data did not contain detail regarding the metastatic site; 
therefore, we did not analyze the prognosis according to the detailed metastatic site. Different patient 
prognoses depending on the metastatic sites and extension have been reported [12, 16]. The detailed 
metastatic sites were reported as PUL (pulmonary), OSS (osseous), HEP (hepatic), BRA (brain), LYM 
(lymph nodes), MAR (bone marrow), PLE (pleura), PER (peritoneum), SKI (skin), and OTH (other) in 
TNM ver. 3 [20]. These evaluations were not adopted in the current version of the TNM classification. 
Nevertheless, these expressions may be convenient for evaluating detailed prognosis according to the 
metastatic site. 
In the current study, the prognosis of in M1a-c mPC treated using PADT was a mean OS of 6.9 years, a 
mean CSS of 8.3 years, a mean PFS of 3.5 years; the 3-year, 5-year, and 10-year survival rates were 68 %, 
53 %, and 34 %, respectively. Reports from western countries have reported that the 5-year and 10-year 
survival rates of patients with mPC were 23 % and 7 %, respectively (SWOG8894; mean age 70.2 years) 
[21], and that the mean OS of patients with mPC treated using CAB was 2.8–3.0 years [22]. The mean 
age of J-CaP patients with M1a-c disease was 73.4 years, which was higher than the age of comparable 
patients in previous reports from western countries. Therefore, Japanese patients with mPC treated using 
PADT had a better prognosis than did those from western countries. Ethnic differences regarding the 
effects of ADT have been reported previously [23], and a large-scale study reported that CSS was higher 
in Japanese PC patients treated using PADT compared with those in the United Stated [24]. 
The present study has some limitations. Because of missing information of some unregistered 
subcategories such as 359 cases of M1x, and so not all patients with mPC in the cohort were enrolled. 
In addition, the treatment and follow-up plans were not unified because the treatment decision-making 
and follow-up schedules were at the discretion of each hospital and the detailed treatment regimens were 
not registered. The evaluations of NM classification were performed using imaging diagnoses; therefore, 
the staging results may be scattered because of differences in the imaging diagnostic capabilities of each 
hospital and no central review of the imaging. The GSs in the current study were not reviewed by central 
pathologist and not influenced by the current ISUP (the International Society of Urological Pathology) 
classification published in 2005 because the registration period was from 2001 to 2003 [25]. Scattering 
may also be possible because local pathologists diagnosed GS. During the follow-up period, novel drugs 
for PC became available, such as zoledronic acid in 2002 for the management of bone metastasis, which 
may have improved the prognosis of patients with mPC [26]. Docetaxel, which has improved the 
prognosis of CRPC, became available in Japan in 2008 [5]. The recently released new drugs for CRPC, 
such as abiraterone [6], enzalutamide [7] and cabazitaxel [8], were likely to have had little influence on 
the current study. Patient prognosis may improve as novel treatments are released. The J-CaP database 
includes a huge number of cases and long-term follow-up from patients that are registered at various 
hospitals all over Japan. Therefore, the results of the current are considered to represent the true clinical 
prognosis of mPC treated using PADT in Japan, regardless of the limitations described above. 
 
Conclusion 
In the current study, the prognoses of patients with mPC was subcategorized according to the TNM 
classification system and treated using PADT in the J-CaP database were analyzed. The prognosis 
worsened as the stage progressed, therefore, current TNM classification system of mPC for PADT was 
shown to be trustworthy; however, there were no significant differences in OS, CSS, and PFS between 
M1a and M1b disease. Each PC cell that develops bone metastasis or lymphoid metastasis may have 
different characteristics. CAB was more effective for the treatment of mPC than was non-CAB in our 
database. 
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Fig. 1.The prognosis of metastatic prostate cancer patients treated using primary androgen deprivation 
therapy. A, overall survival (OS); B, cancer-specific survival (CSS); C, progression-free survival (PFS). 








  N1M0 M1a M1b M1c 
5 –year OS (95%CI) 76.0% (72.1-79.9) 57.5% (48.8-66.2) 54.0% (52.0-56.0) 40.0% (32.1-47.9) 
OS, HR (95%CI) Reference 1.966 (1.498-2.581) 2.200 (1.864-2.595) 3.181 (2.509-4.033) 
  0.453 (0.384-0.535) 0.893 (0.711-1.121) Reference 1.446 (1.203-1.739) 
No. at risk 
N1M0               730                  496                 309                 187                 112                  57                    13 
M1a                  224                  136                   66                  37                   26                   13                      2 
M1b                4386                2479               1246                632                 326                 169                    25   






  N1M0 M1a M1b M1c 
5 –year CSS (95%CI) 83.2% (79.7-86.7) 69.0% (60.7-77.3) 63.1% (61.1-65.1) 51.5% (43.2-59.8) 
CSS, HR (95%CI) Reference 2.120 (1.508-2.982) 2.582 (2.091-3.187) 3.930 (2.948-5.240) 
  0.386 (0.313-0.477) 0.821 (0.62-1.087) Reference 1.521 (1.229-1.881) 
No. at risk 
N1M0               730                  496                 309                  187                  112                  57                  13 
M1a                  224                  136                   66                   37                     26                  13                    2 
M1b                4386                2479               1246                 632                   326                169                  25   




  N1M0 M1a M1b M1c 
5 –year  PFS (95%CI) 38.8% (34.3-43.3) 23.0% (15.9-30.1) 23.0% (21.4-24.6) 16.6% (11.1-22.1) 
PFS, HR (95%CI) Reference 1.838 (1.518-2.226) 1.796 (1.608-2.006) 2.308 (1.934-2.755) 
  0.556 (0.498-0.621) 1.023 (0.868-1.207) Reference 1.279 (1.104-1.482) 
No. at risk 
N1M0                730                  388                  192                  89                    56                    29                     7 
M1a                   224                    81                   34                   14                      8                      4                   
M1b                 4386                1539                 627                 285                  139                    76                     9   
M1c                   278                    77                   31                     9                      7                       1                     
Table 1 Patient's background grouped by M stage
Characteristic N1M0 M1a M1b M1c
Number 730 224 4386 278
Age, mean (±SD)* 72.6 (±8.2) 71.6 (±7.5) 73.6 (±8.2) 71.6 (±8.3)
　<60, n (%) 43 (5.9%) 12 (5.4%) 223 (5.1%) 22 (7.9%)
　60–64, n (%) 70 (9.6%) 26 (11.6%) 377 (8.6%) 26 (9.4%)
　65–69, n (%) 121 (16.6%) 43 (19.2%) 673 (15.3%) 51 (18.3%)
　70–74, n (%) 191 (26.2%) 64 (28.6%) 1064 (24.3%) 72 (25.9%)
　75–80, n (%) 165 (22.6%) 47 (21.0%) 1009 (23.0%) 66 (23.7%)
　80–85, n (%) 88 (11.5%) 21 (9.4%) 627 (14.3%) 27 (9.7%)
　>85, n (%) 52 (7.1%) 11 (4.9%) 413 (9.4%) 14 (5.0%)
PSA, mean (±SD)** 278.5（±869.0） 607.9（±1402.9） 940.5（±2150.8） 1473.6（±2757.6）
 <20, n (%) 140 (19.2%) 25 (11.2%) 583 (13.3%) 30 (10.8%)
 20–100, n (%) 271 (37.1%) 56 (25.0%) 1028 (23.4%) 67 (24.1%)
 100–500, n (%) 235 (32.2%) 91 (40.6%) 1309 (29.8%) 72 (25.9%)
 >500, n (%) 84 (11.5%) 52 (23.2%) 1466 (33.4%) 109 (39.2%)
GS, mean(±SD)*** 7.7 (±1.4) 8.2 (±1.4) 7.7 (±1.4) 7.8 (±1.3)
 <6, n (%) 103 (16.2%) 21 (10.8%) 573 (15.4%) 31 (12.8%)
 7, n (%) 184 (29.0%) 39 (20.0%) 1039 (27.9%) 69 (28.4%)
 8, n (%) 116 (18.3%) 31 (15.9%) 761 (20.4%) 56 (23.0%)
 9–10, n (%) 634 (13.2%) 104 (53.3%) 1355 (36.3%) 87 (35.8%)
Criteria of hormone therapy#
 CAB, n (%) 484 (66.3%) 155 (69.2%) 3045 (69.4%) 180 (64.7%)
 Non CAB, n (%) 246 (33.7%) 69 (30.8%) 1341 (30.6%) 98 (35.3%)
SD: standard deviation, PSA: prostate specific antigen, GS: Gleason score, CAB: combined androgen brockade
* Age; N1M0 vs M1b, M1a vs M1b, M1b vs M1c; p  < 0.05
**PSA; N1M0 vs M1b, N1M0 vs M1c, M1a vs M1c, M1b vs M1c; p  < 0.05
***Gleason score; N1M0 vs M1a, M1a vs M1b, M1a vs M1c, p < 0.05
# chi-square test; p  = 0.167
Table 2. Multivariate analysis of factors that impact on overall survival in patients at different stages
Factor N1M0 M1a M1b M1c
n (%) HR 95% CI p  value n (%) HR 95% CI p  value n (%) HR 95% CI p  value n (%) HR 95% CI p  value
Age 0.046 0.524 <0.001 0.007
<75 364 (57.5) Ref. 123 (63.0) Ref. 1980 (53.1) Ref. 146 (60.0) Ref.
>75 269 (42.5) 1.41 1.007-1.981 72 (37.0) 1.17 0.718-1.919 1748 (46.9) 1.27 1.138-1.414 97 (40.0) 1.72 1.162-2.542
GS 0.026 0.003 <0.001 0.003
<7 287 (45.3) Ref. 60 (30.8) Ref. 1612 (43.2) Ref. 100 (41.2) Ref.
>8 346 (54.7) 1.5 1.050-2.132 135 (69.2) 2.5 1.361-4.586 2116 (56.8) 1.53 1.369-1.718 143 (58.8) 1.85 1.226-2.788
PSA 0.782 0.03 <0.001 0.789
<100 356 (56.2) Ref. 68 (34.9) Ref. 1325 (35.5) Ref. 80 (32.8) Ref.
>100 277 (43.8) 1.05 0.747-1.472 127 (65.1) 0.57 0.348-0.947 2403 (64.5) 1.47 1.306-1.662 163 (67.1) 0.95 0.625-1.430
Teatment 0.016 0.12 <0.001 0.023
Non-CAB 222 (35.1) Ref. 131 (67.2) Ref. 1124 (30.2) Ref. 87 (35.8) Ref.
CAB 411 (64.9) 0.66 0.469-0.925 64 (32.8) 0.82 0.644-1.052 2604 (69.8) 0.75 0.666-0.837 156 (64.2) 0.63 0.423-0.937
HR: hazard ratio, CI: confidence interval, GS: Gleason score, PSA: prostate specific antigen, CAB: combined androgen blockade
 
Table 3. Multivariate analysis of factors that impact on cancer specific survival in patients at different stages
Factor N1M0 M1a M1b M1c
HR 95% CI p  value HR 95% CI p  value HR 95% CI p  value HR 95% CI p  value
Age 0.784 0.584 0.742 0.097
<75 Ref. Ref. Ref. Ref.
>75 0.94 0.605-1.460 0.837 0.443-1.582 0.98 0.858-1.115 1.479 0.931-2.348
GS 0.003 0.001 <0.001 0.001
<7 Ref. Ref. Ref. Ref.
>8 2.06 1.283-3.308 4.582 1.899-11.053 1.67 1.455-1.913 2.331 1.409-3.857
PSA 0.616 0.020 <0.001 0.788
<100 Ref. Ref. Ref. Ref.
>100 0.894 0.578-1.384 0.486 0.264-0.894 1.670 1.440-1.937 0.936 0.579-1.513
Teatment 0.006 0.254 <0.001 0.009
Non-CAB Ref. Ref. Ref. Ref.
CAB 0.548 0.355-0.845 0.702 0.383-1.289 0.76 0.661-0.868 0.544 0.344-0.861
HR: hazard ratio, CI: confidence interval, GS: Gleason score, PSA: prostate specific antigen, CAB: combined androgen blockade
